Business Context and Reporting Period
This Form 8-K Current Report was filed by Vaxcyte, Inc. on September 4, 2024, with the report date of September 6, 2024. The filing discloses the execution of an underwriting agreement for a public offering of common stock and pre-funded warrants.
Key Financial Metrics and Transaction Details
- Offering Structure: Sale of 10,194,175 shares of common stock and 2,427,184 pre-funded warrants.
- Public Price: Common stock at $103.00 per share; pre-funded warrants at $102.999 per warrant.
- Underwriter Price: Common stock at $98.1075 per share; pre-funded warrants at $98.1065 per warrant.
- Over-Allotment Option: Underwriters exercised their option in full to purchase an additional 1,893,203 shares of common stock on September 5, 2024.
- Net Proceeds: Expected to be approximately $1.42 billion after deducting underwriting discounts, commissions, and estimated offering expenses.
- Closing Date: Expected on or about September 6, 2024.
Material Changes
The filing does not provide comparative financial data (revenue, profit, or cash flow) as it is a current report regarding a capital raise event rather than a periodic financial statement. The material change is the significant increase in liquidity and equity capitalization resulting from the $1.42 billion gross offering.
Outlook, Risks, and Management Commentary
The offering is being made pursuant to an effective registration statement on Form S-3. The underwriting agreement includes customary representations, warranties, covenants, and indemnification obligations. The closing is subject to the satisfaction of customary closing conditions. No specific operational guidance or risk factors beyond standard underwriting terms are detailed in this specific filing text.
Investor Verification Checklist
- Verify the final closing date and confirmation of the $1.42 billion net proceeds.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific lock-up periods and indemnification clauses.
- Confirm the dilution impact of the total shares issued (including the over-allotment) on existing shareholders.
- Check subsequent filings for the actual use of proceeds as disclosed in the prospectus supplement.